Belantamab Mafodotin (Belamaf) for Relapsed/Refractory Multiple Myeloma (RRMM): A Real-World Observational Study
Authors:
Open Access
- 15 November 2022
- journal article
- abstracts
- Published by American Society of Hematology in Blood
- Vol. 140 (Supplement) , 10124-10126